Sarepta Therapeutics, Inc. Q1 2021 Earnings Conference Call
Forward Looking Statements

Wednesday, May 5, 2021 – 4:30 p.m. Eastern Time

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities and research and development programs, including: the potential of AMONDYS 45 to treat about 8% of children with an exon 45 amenable mutation; the potential of our three products to offer therapy to nearly 30% of children with Duchenne in the U.S.; our constructs' potential to offer therapy to about 80% of the Duchenne community; the potential to bring our therapies to patients outside of the U.S.; PPMO's potential to achieve much greater tissue exposure, greater exon skipping, and therefore greater dystrophin production; PPMO's potential to transform our RNA platform in the U.S. and internationally, multiplying the potential Duchenne population who will have access to our therapies; PPMO's potential to treat other disease areas; our belief that our new process in SRP-9001-103 will achieve expression levels higher than the 28.1% seen in Part 1 of the study; the potential of SRP-9001 to be a significant advancement in the treatment of Duchenne and a greatly differentiated and enhanced gene therapy, in terms of safety, expression, and benefit; our expectation that the demographics for AMONDYS 45 will be similar to our other two populations with regard to the average age of patients on therapy and payer mix; the future impact of COVID-19 on our commercialization; our goal to help mitigate the risks and potential impact of COVID-19 on the Duchenne patients we serve; the competitive impact on the growth trajectory of new patient starts; our prediction that SRP-5051 will achieve greater than 10% dystrophin with monthly dosing over time; our belief that, for SRP-5051, serum monitoring of magnesium and oral supplementation with magnesium is a feasible approach to enable early detection and management going forward; and expected plans and milestones, including discussing with the FDA the path for the commencement of Part B of our MOMENTUM trial, the goal to make Part B of MOMENTUM our pivotal trial and to seek accelerated approval in the U.S., engaging with ministries of health ex-US about the clinical path for our PPMO therapies, our plan to meet with the FDA around mid-2021 and commence our next trial for SRP-9001 as soon thereafter as is possible, presenting expression and safety results from the first cohort of SRP-9001-103 in Q2 2021, presenting additional results from Part 2 of Study SRP-9001-102 in early 2022, working with FDA in the second half of 2021 to devise an efficient and executable path to approval of SRP-9003 and our 6-program LGMD portfolio, and commencing a pivotal trial of SRP-9003 in 2021.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to sales of our products or attain the anticipated net revenues, profitability or positive cash-flow from operations; we may not be able to comply with all FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; our dependence on certain manufacturers to produce our products and product candidates, including any inability on our part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; our data for SRP-5051, SRP-9001, the LGMD programs and/or other programs may not be sufficient for obtaining regulatory approval; success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; the commencement and completion of our clinical trials and announcement of results may be delayed or prevented for a number of reasons, including, among others, denial by the regulatory agencies of permission to proceed with our clinical trials, or placement of a clinical trial on hold, challenges in identifying, recruiting, enrolling and retaining patients to participate in clinical trials and inadequate quantity or quality of supplies of a product candidate or other materials necessary to conduct clinical trials; if the actual number of patients suffering from Duchenne is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, many of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the COVID-19 pandemic; and those risks identified under the heading "Risk Factors" in our most recent Annual Report on Form 10-K for the year ended December 31, 2020 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.